ACP
NERV icon

Acuta Capital Partners’s Minerva Neurosciences NERV Stock Holding History

Acuta Capital Partners’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.94M Hold
709,500
– – 2.74% 14
2026
Q1 		$4.27M Hold
709,500
– – 3.02% 11
2025
Q4 		$2.85M Buy
+709,500
New +$2.63M 1.94% 13

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acuta Capital Partners's NERV Position: Q2 2026 in Review

Acuta Capital Partners held its Minerva Neurosciences (NERV) position steady in Q2 2026 at 709,500 shares worth $3.94M. The position accounts for 2.74% of the portfolio, ranked #14.

Acuta Capital Partners first reported a position in NERV in Q4 2025 and has held it in 3 quarters since. The position peaked at $4.27M in Q1 2026. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Acuta Capital Partners held 709,500 shares of Minerva Neurosciences worth $3.94M as of Q2 2026.
  • Acuta Capital Partners left its Minerva Neurosciences share count unchanged in Q2 2026.
  • Minerva Neurosciences made up 2.74% of Acuta Capital Partners's portfolio in Q2 2026, its #14 holding.
  • Acuta Capital Partners first reported a position in Minerva Neurosciences in Q4 2025 and has held it in 3 quarters since.
  • Acuta Capital Partners's Minerva Neurosciences position peaked at $4.27M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.